Vanguard Group
CAI

Vanguard Group’s Caris Life Sciences CAI Stock Holding History

Vanguard Group’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$904K Sell
33,505
-142,039
-81% -$4M ﹤0.01% 3801
2025
Q3 		$5.31M Buy
175,544
+25,544
+17% +$815K ﹤0.01% 3258
2025
Q2 		$4.01M Buy
+150,000
New +$4.04M ﹤0.01% 3290

Other funds holding CAI

JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group's CAI Position: Q4 2025 in Review

Vanguard Group reduced its Caris Life Sciences (CAI) stake by 81% in Q4 2025, selling an estimated $4M and leaving 33,505 shares worth $904K. The position accounts for ﹤0.01% of the portfolio, ranked #3801.

Vanguard Group first reported a position in CAI in Q2 2025 and has held it in 3 quarters since. The position peaked at $5.31M in Q3 2025. 186 funds tracked by Wall St. Rank hold CAI as of Q4 2025.

  • Vanguard Group held 33,505 shares of Caris Life Sciences worth $904K as of Q4 2025.
  • Vanguard Group sold 142,039 Caris Life Sciences shares in Q4 2025, an estimated $4M.
  • Caris Life Sciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3801 holding.
  • Vanguard Group first reported a position in Caris Life Sciences in Q2 2025 and has held it in 3 quarters since.
  • Vanguard Group's Caris Life Sciences position peaked at $5.31M in Q3 2025.
  • 186 funds tracked by Wall St. Rank held Caris Life Sciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.